Efficacy and Safety of Antipsychotics for the Treatment of Major Depressive Disorder in Adolescents and Adults: Current Issues and Clinical Perspective


Objectives: Atypical antipsychotics are increasingly being prescribed for the treatment of mood disorders, often off-label. This review describes existing published literature on the efficacy and safety of antipsychotics for the treatment of major depressive disorder (MDD) in adults and adolescents. We discuss current clinical considerations: role as monotherapy, adjunctive, or augmentation therapy, side effect profiles, and optimal dose and duration of therapy. Potential areas for future research and methodological considerations are also highlighted. Method: We conducted a literature search of MEDLINE, EMBASE, PsycINFO, and Cochrane databases. Relevant articles and references were identified. MDD practice guidelines for adolescents and adults were reviewed. Results: Evidence for using atypical antipsychotics to treat MDD is heterogeneous. It is thus difficult to draw firm conclusions regarding their role in therapy. Most current guidelines do not include recommendations for atypical antipsychotics, but off-label use is common in clinical practice. Primary use is adjunct or augmentation therapy for treatment resistant depression. Potential benefits versus side effects must be cautiously considered, especially for children and adolescents. Clinicians must rely on their clinical experience and professional judgment to determine an optimal dose and duration of therapy. Conclusions: There is progressive research to support the use of atypical antipsychotics to treat MDD in adults. However, additional research and well-designed studies are needed to determine the appropriate and safe use of atypical antipsychotics for treating child and adolescent depression. Other subpopulations that may benefit from combination therapy, such as individuals with dual diagnoses, may be identified through future research.

Share and Cite:

Rasasingham, R. (2014) Efficacy and Safety of Antipsychotics for the Treatment of Major Depressive Disorder in Adolescents and Adults: Current Issues and Clinical Perspective. Open Journal of Psychiatry, 4, 182-188. doi: 10.4236/ojpsych.2014.43024.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Lam, R.W., et al. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. III. Pharmacotherapy. Journal of Affective Disorders, 117, S26-S43. http://dx.doi.org/10.1016/j.jad.2009.06.041
[2] Corya, S.A., et al. (2006) A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, Fluoxetine, and Venlafaxine in Treatment-Resistant Depression. Depression and Anxiety, 23, 364-372. http://dx.doi.org/10.1002/da.20130
[3] Shelton, R.C., Williamson, D.J., Corya, S.A., Sanger, T.M., Van Campen, L.E., Case, M., Briggs, S.D. and Tollefson, G.D. (2005) Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression: A Controlled Study of SSRI and Nortriptyline Resistance. The Journal of clinical psychiatry, 66, 1289-1297. http://dx.doi.org/10.4088/JCP.v66n1012
[4] Thase, M.E., Corya, S.A., Osuntokun, O., Case, M., Henley, D.B., Sanger, T.M., Watson, S.B. and Dubé, S. (2007) A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder. The Journal of Clinical Psychiatry, 68, 224-236. http://dx.doi.org/10.4088/JCP.v68n0207
[5] McIntyre, A. and Gendron, A. (2007) Selective Serotonin Reuptake Inhibitors or Venlafaxine in Patients with Major Depression, Comorbid Anxiety, and Residual Depressive Symptoms: A Randomized, Placebo. Depression and Anxiety, 494, 487-494.
[6] Bauer, M., Pretorius, H.W., Constant, E.L., Earley, W.R., Szamosi, J. and Brecher, M. (2009) Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients with Major Depressive Disorder: Results of a Randomized, Placebo-Controlled, Double-Blind Study. The Journal of Clinical Psychiatry, 70, 540-549. http://dx.doi.org/10.4088/JCP.08m04629
[7] El-Khalili, N., Joyce, M., Atkinson, S., Buynak, R.J., Datto, C., Lindgren, P. and Eriksson, H. (2010) Extended-Release Quetiapine Fumarate (Quetiapine XR) as Adjunctive Therapy in Major Depressive Disorder (MDD) in Patients with an Inadequate Response to Ongoing Antidepressant Treatment: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study. The International Journal of Neuropsychopharmacology, 13, 917-932. http://dx.doi.org/10.1017/S1461145710000015
[8] Rapaport, M.H., et al. (2006) Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation. Neuropsychopharmacology, 31, 2505-2513. http://dx.doi.org/10.1038/sj.npp.1301113
[9] Keitner, G.I., Garlow, S.J., Ryan, C.E., Ninan, P.T., Solomon, D.A., Nemeroff, C.B. and Keller, M.B. (2009) A Randomized, Placebo-Controlled Trial of Risperidone Augmentation for Patients with Difficult-to-Treat Unipolar, Non-Psychotic Major Depression. Journal of Psychiatric Research, 43, 205-214. http://dx.doi.org/10.1016/j.jpsychires.2008.05.003
[10] Mahmoud, R., Pandina, G.J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C.M., Kujawa, M.J. and Gharabawi-Garibaldi, G.M. (2007) Risperidone for Treatment-Refractory Major Depressive Disorder. Annals of Internal Medicine, 147, 593-602. http://dx.doi.org/10.7326/0003-4819-147-9-200711060-00003
[11] Kennedy, S.H., Lam, R.W., Parikh, S.V., Patten, S.B. and Ravindran, A.V. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. Introduction. Journal of Affective Disorders, 117, S1-S2.
[12] Birmaher, B. and Brent, D. (2007) Practice Parameter for the Assessment and treatment of Children and Adolescents with Depressive Disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1503-1526. http://dx.doi.org/10.1097/chi.0b013e318145ae1c
[13] Findling, R.L., et al. (2011) Practice Parameter for the Use of Atypical Antipsychotic Medications in Children and Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry.
[14] National Institute for Health and Clinical Excellence (2005) Depression in Children and Young People. CG28 (September).
[15] McIntyre, R.S. and Jerrell, J.M. (2009) Polypharmacy in Children and Adolescents Treated for Major Depressive Disorder: A Claims Database Study. The Journal of Clinical Psychiatry, 70, 240-246. http://www.ncbi.nlm.nih.gov/pubmed/19192465 http://dx.doi.org/10.4088/JCP.08m04212
[16] Díaz-Caneja, C.M., et al. (2012) Polypharmacy with Antidepressants in Children and Adolescents. The International Journal of Neuropsychopharmacology, 17, 1063-1082.
[17] Olfson, M., Blanco, C., Liu, S.M., Wang, S. and Correll, C.U. (2012) National Trends in the Office-Based Treatment of Children, Adolescents, and Adults with Antipsychotics. Archives of General Psychiatry, 69, 1247-1256.
http://www.ncbi.nlm.nih.gov/pubmed/22868273 http://dx.doi.org/10.1001/archgenpsychiatry.2012.647
[18] Vitiello, B., Correll, C., van Zwieten-Boot, B., Zuddas, A., Parellada, M. and Arango, C. (2009) Antipsychotics in Children and Adolescents: Increasing Use, Evidence for Efficacy and Safety Concerns. European Neuropsychopharmacology, 19, 629-635.
http://www.ncbi.nlm.nih.gov/pubmed/19467582 http://dx.doi.org/10.1016/j.euroneuro.2009.04.008
[19] Fountoulakis, K. and Nimatoudis, I. (2004) Off-Label Indications for Atypical Antipsychotics: A Systematic Review. Annals of General Hospital Psychiatry, 3, 4.
[20] Fleurence, R., Williamson, R., Jing, Y., Kim, E., Tran, Q.V., Pikalov, A.S. and Thase, M.E. (2009) A Systematic Review of Augmentation Strategies for Patients with Major Depressive Disorder. Psychopharmacology Bulletin, 42, 57-90.
[21] Papakostas, G.I., Shelton, R.C., Smith, J. and Fava, M. (2007) Augmentation of Antidepressants with Atypical Antipsychotic Medications for Treatment-Resistant Major Depressive Disorder: A Meta-Analysis. Journal of Clinical Psychiatry, 68, 826-831. http://dx.doi.org/10.4088/JCP.v68n0602
[22] Nelson, J. and Papakostas, G. (2009) Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials. American Journal of Psychiatry, 166, 980-991. http://dx.doi.org/10.1176/appi.ajp.2009.09030312
[23] Farahani, A. and Correll, C.U. (2012) Are Antipsychotics or Antidepressants Needed for Psychotic Depression? A Systematic Review and Meta-Analysis of Trials Comparing Antidepressant or Antipsychotic Monotherapy with Combination Treatment. The Journal of Clinical Psychiatry, 73, 486-496. http://dx.doi.org/10.4088/JCP.11r07324
[24] Chen, J., Gao, K.M. and Kemp, D.E., (2011) Second-Generation Antipsychotics in Major Depressive Disorder: Update and Clinical Perspective. Current Opinion in Psychiatry, 24, 10-17.
[25] Komossa, K., Depping, A. and Gaudchau, A., (2012) Second-Generation Antipsychotics for Major Depressive Disorder and Dysthymia (Review). Cochrane Database of Systematic Reviews.
[26] Garcia-Toro, M., Medina, E., Galan, J.L., Gonzalez, M.A. and Maurino, J. (2012) Treatment Patterns in Major Depressive Disorder after an Inadequate Response to First-Line Antidepressant Treatment. BMC Psychiatry, 12, 143.
abstract http://dx.doi.org/10.1186/1471-244X-12-143
[27] Cohen, D., Bonnot, O., Bodeau, N., Consoli, A. and Laurent, C. (2012) Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents: A Bayesian Meta-Analysis. Journal of Clinical Psychopharmacology, 32, 309-316. http://dx.doi.org/10.1097/JCP.0b013e3182549259
[28] Gao, K.M., et al. (2011) Number Needed to Treat to Harm for Discontinuation Due to Adverse Events in the Treatment of Bipolar Depression, Major Depressive Disorder, and Generalized. The Journal of Clinical Psychiatry, 72, 1063-1071. http://dx.doi.org/10.4088/JCP.09r05535gre
[29] Ormerod, S., McDowell, S.E., Coleman, J.J. and Ferner, R.E. (2008) Ethnic Differences in the Risks of Adverse Reactions to Drugs Used in the Treatment of Psychoses and Depression. Drug Safety, 31, 597-607. http://dx.doi.org/10.2165/00002018-200831070-00005
[30] Kalsekar, I., Wagner, J.-S., DiBonaventura, M., Bates, J., Forbes, R. and Hebden, T. (2012) Comparison of Health-Related Quality of Life among Patients Using Atypical Antipsychotics for Treatment of Depression: Results from the National Health and Wellness Survey. Health and Quality of Life Outcomes, 10, 81. http://dx.doi.org/10.1186/1477-7525-10-81
[31] Christian, R., et al. (2012) Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults. Agency for Healthcare Research and Quality, Rockville.
[32] Lev-Ran, S., Aviram, A., Braw, Y., Nitzan, U., Ratzoni, G. and Fennig, S. (2012) Clinical Correlates of Cannabis Use among Adolescent Psychiatric Inpatients. European Psychiatry, 27, 470-475.
[33] Brown, E.S., Nejtek, V.A., Perantie, D.C. and Bobadilla, L. (2002) Quetiapine in Bipolar Disorder and Cocaine Dependence. Bipolar Disorders, 4, 406-411.
[34] Price, S.A. and Brahm, N.C. (2011) Antipsychotic Treatment of Adolescent Dual Diagnosis Patients. The Journal of Pediatric Pharmacology and Therapeutics, 16, 226-236.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.